Friday, 27 Mar 2020

You are here

Female "Viagra Pill" Controversy - Grandstanding or Equal Rights?

The FDA is under pressure over the recent approval of the "female viagra" pill.  On August 18th, the FDA announced its approval for Addyi (flibanserin) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Prior to Addyi’s approval, there were no FDA-approved treatments for sexual desire disorders in men or women.  This latter issue became one of the dominant themes during the FDA advisory board that preceded the decision.  

The theme presented by the manufacturers was "26-0", meaning there were 26 approved drugs for male libido and none for women.  In addition there were many impassioned pleas for approval from patients and others during the open forum presentations. 

Despite the "unmet need" for such therapy, insurers and reviewers have remarked that the evidence for the drugs efficacy is minimal and that there is a problematic interaction with alcohol that requires more study. For instance, In these trials, treatment with flibanserin increased the number of satisfying sexual events by 0.5 to one additional event per month over placebo, increased the sexual desire score by 0.3 to 0.4 over placebo, and decreased their (sexual) distress score related to sexual desire by 0.3 to 0.4 over placebo.

Like Viagra, it is unlikely that this medication will be covered by insurance. Moreover, physicians who wish to prescribe it will be required by the FDA to complete an online training program to be authorized to prescribe it, and patients will be required to sign a form acknowlegingthe risks.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Rheumatic Disease Drugs and COVID-19

We are in the early stages of trying to limit the morbid and mortal consequences of the corona virus pandemic of 2020. Not surprisingly, the recommendations designed to limit exposure and damage continually highlight the fact that the elderly and immunosuppressed may be amongst the most severely affected should they become infected with this virus. This has led to a great deal of uncertainty by patients and providers about how rheumatic diseases and their treatments need to be specifically addressed.

EMA Final Recommendations on VTE Risk with Tofacitinib

On 14 November 2019 the European Medicines Agency (EMA) concluded that Xeljanz (tofacitinib) could increase the risk of blood clots in the lungs and in deep veins in patients who are already at high risk.  These recommendations have been formally published and are intended for EU nations utilizing tofacitinib.

Drug Interactions with Cannabinoids

Cannbinoids are widely available and used for a variety of indications, but little is known about their safety and their potential for drug interactions. The Canadian Medical Journal has published a review of drug interactions with cannabinoids, many of which are mediated by cytochrome-P450 metabolism.

Overmedication of America

Recent research from the Lown Institute reports that 750 older Americans are hospitalized daily because of serious side effects from and the core problem is that of polypharmacy, especially in the elderly. 

Best of 2019 - Biologic Safety Guidelines from the British Society for Rheumatology

In the United Kingdom, NICE has looked to the British Society of Rheumatology (BSR) to develop evidence based guidance on the safe use of biologic DMARDs in patients with inflammatory arthritis. This guidance document on biologic safety covers baseline screening, monitoring, effect of co-morbidities, and when or under what circumstances biologic therapy should be interrupted.